Celltex- AdMSCs
Phase 2Biologic
Celltex- AdMSCs is one of 22 biologic programs targeting Osteoarthritis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Toradol
RochePreclinical
Cataflam
NovartisPreclinical
Platelet Rich Plasma
ZZagazig University
Preclinical
Voltaren
CCerimon Pharmaceuticals
Preclinical
Enbrel
IImmunex
Preclinical
Paracetamol
GSKPreclinical
Naproxen Sodium
BayerPreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Ansaid
PPharmacia and Upjohn
Preclinical
Celltex- AdMSCs
CCelltex Therapeutics Corporation
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Celltex- AdMSCs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- CCelltex Therapeutics Corporation